ATNM Actinium Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NYSEAMERICAN: ATNM

Price (delayed)

$1.115

Market cap

$34.98M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.75

Enterprise value

-$5.63M

?
Relative Growth: Rel. Growth: 20
Relative Strength: Rel. Strength: 24
Relative Valuation: Rel. Valuation: 1
Relative Profitability: Rel. Profitability: 33

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. Actinium's lead application ...

Highlights
The EPS has grown by 49% YoY and by 31% from the previous quarter
ATNM's net income is up by 48% year-on-year and by 31% since the previous quarter
The debt has decreased by 10% from the previous quarter but it has increased by 6% YoY
The equity has dropped by 91% year-on-year and by 71% since the previous quarter
The quick ratio has decreased by 38% YoY and by 4.8% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.actiniumpharma.com
Peers: KMDA BMRN

Key stats

What are the main financial stats of ATNM

ATNM stock price

How has the Actinium Pharmaceuticals stock price performed over time
Intraday
-3.88%
1 week
-3.04%
1 month
-7.08%
1 year
-34.8%
YTD
-18.01%
QTD
12.03%

Financial performance

How have Actinium Pharmaceuticals's revenue and profit performed over time
Revenue
$90,000
Gross profit
$90,000
Operating income
-$25.51M
Net income
-$23.47M
Gross margin
100%
Net margin
-26,078.9%
ATNM's net income is up by 48% year-on-year and by 31% since the previous quarter
The operating income has increased by 48% year-on-year and by 30% since the previous quarter
The net margin has increased by 31% from the previous quarter
Actinium Pharmaceuticals's operating margin has increased by 30% from the previous quarter

Price vs fundamentals

How does ATNM's price correlate with its fundamentals

Growth

What is Actinium Pharmaceuticals's growth rate over time

Valuation

What is Actinium Pharmaceuticals stock price valuation
P/E
N/A
P/B
15.18
P/S
387
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-62.55
The EPS has grown by 49% YoY and by 31% from the previous quarter
The price to book (P/B) is 155% higher than the last 4 quarters average of 6.2
The equity has dropped by 91% year-on-year and by 71% since the previous quarter
ATNM's price to sales (P/S) is 63% less than its 5-year quarterly average of 1080.1

Efficiency

How efficient is Actinium Pharmaceuticals business performance
ATNM's return on equity has dropped by 69% year-on-year and by 7% since the previous quarter
The ROS has grown by 31% from the previous quarter
The company's return on assets rose by 24% YoY and by 23% QoQ

Dividends

What is ATNM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ATNM.

Financial health

How did Actinium Pharmaceuticals financials performed over time
Actinium Pharmaceuticals's total assets is 5% more than its total liabilities
The quick ratio has decreased by 38% YoY and by 4.8% from the previous quarter
Actinium Pharmaceuticals's current ratio has decreased by 37% YoY and by 5% QoQ
The debt is 34% less than the equity
The company's debt to equity has surged by 200% QoQ
The equity has dropped by 91% year-on-year and by 71% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.